Format

Send to

Choose Destination
Dement Geriatr Cogn Disord. 2015;39(1-2):68-80. doi: 10.1159/000367685. Epub 2014 Oct 24.

Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.

Author information

1
Centre for Functional and Metabolic Mapping (CFMM), Robarts Research Institute, and Department of Medical Biophysics, University of Western Ontario, London, Ont., Canada.

Abstract

AIM:

To determine whether 4 months of rivastigmine treatment would result in metabolic changes and whether metabolic changes correlate with changes in cognition in people with Alzheimer's disease (AD).

METHODS:

Magnetic resonance spectra were acquired from the posterior cingulate cortex of subjects with AD at 3 T. Magnetic resonance imaging scans and cognitive tests were performed before and 4 months after the beginning of the treatment. Metabolite concentrations were quantified and used to calculate the metabolite ratios.

RESULTS:

On average, the N-acetylaspartate/creatine (NAA/Cr) ratio decreased by 12.7% following 4 months of rivastigmine treatment, but changes in the NAA/Cr ratio correlated positively with changes in Mini-Mental State Examination scores.

CONCLUSION:

This positive correlation between changes in NAA/Cr and changes in cognitive performance suggests that the NAA/Cr ratio could be an objective indicator of a response to rivastigmine treatment.

PMID:
25358336
DOI:
10.1159/000367685
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center